UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q


                Quarterly Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934


                For the quarterly period ended November 27, 1999
                                               -----------------


                         Commission file number 1-11479
                                                -------


                                  E-Z-EM, Inc.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                  Delaware                               11-1999504
       -------------------------------                 --------------
       (State or other jurisdiction of                (I.R.S. Employer
        incorporation or organization)               Identification No.)


            717 Main Street, Westbury, New York            11590
         ----------------------------------------        ---------
         (Address of principal executive offices)        (Zip Code)


                                 (516) 333-8230
               --------------------------------------------------
               Registrant's telephone number, including area code



Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

                                  Yes _X_ No___


On January 7, 2000,  there were  4,026,220  shares of the  registrant's  Class A
Common Stock outstanding and 5,969,344 shares of the registrant's Class B Common
Stock outstanding.




                                  Page 1 of 21
                            Exhibit Index on Page 19


<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

                                      INDEX
                                      -----


Part I:  Financial Information                                        Page
------   ---------------------                                        ----

    Item 1.  Financial Statements

       Consolidated Balance Sheets - November 27, 1999 and
          May 29, 1999                                                3 - 4

       Consolidated Statements of Earnings - thirteen and
          twenty-six weeks ended November 27, 1999 and
          November 28, 1998                                             5

       Consolidated Statement of Stockholders' Equity and
          Comprehensive Income - twenty-six weeks ended
          November 27, 1999                                             6

       Consolidated Statements of Cash Flows - twenty-six weeks
          ended November 27, 1999 and November 28, 1998               7 - 8

       Notes to Consolidated Financial Statements                     9 - 12

    Item 2.  Management's Discussion and Analysis of Financial
                    Condition and Results of Operations              13 - 18

    Item 3.  Quantitative and Qualitative Disclosures About
                    Market Risk                                        18

Part II:  Other Information
--------  -----------------

    Item 4.  Submission of Matters to a Vote of Security Holders       19

    Item 6.  Exhibits and Reports on Form 8-K                          19



                                      -2-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

                           CONSOLIDATED BALANCE SHEETS
                                 (in thousands)


                                                    November 27,        May 29,
              ASSETS                                    1999             1999
                                                       ------           ------
                                                    (unaudited)        (audited)

CURRENT ASSETS
    Cash and cash equivalents                        $  6,412           $ 8,073
    Debt and equity securities                          8,874             5,216
    Accounts receivable, principally
       trade, net                                      23,827            21,904
    Inventories                                        28,171            26,974
    Other current assets                                3,550             4,151
                                                      -------            ------

          Total current assets                         70,834            66,318

PROPERTY, PLANT AND EQUIPMENT - AT COST,
    less accumulated depreciation and
    amortization                                       21,012            21,325

COST IN EXCESS OF FAIR VALUE OF NET ASSETS
    ACQUIRED, less accumulated amortization               417               424

INTANGIBLE ASSETS, less accumulated
    amortization                                        2,236             2,328

DEBT AND EQUITY SECURITIES                              4,534             3,015

OTHER ASSETS                                            2,815             2,649
                                                      -------            ------

                                                     $101,848           $96,059
                                                      =======            ======




The accompanying notes are an integral part of these statements.


                                      -3-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

                           CONSOLIDATED BALANCE SHEETS
                 (in thousands, except share and per share data)


                                                         November 27,   May 29,
    LIABILITIES AND STOCKHOLDERS' EQUITY                    1999         1999
                                                           ------       ------
                                                         (unaudited)   (audited)

CURRENT LIABILITIES
    Notes payable                                                       $ 1,829
    Current maturities of long-term debt                  $    227          197
    Accounts payable                                         8,578        7,320
    Accrued liabilities                                      8,034        7,736
    Accrued income taxes                                       666          806
                                                           -------       ------

          Total current liabilities                         17,505       17,888

LONG-TERM DEBT, less current maturities                      1,714          477

OTHER NONCURRENT LIABILITIES                                 2,799        2,403

COMMITMENTS AND CONTINGENCIES

                                                           -------       ------
          Total liabilities                                 22,018       20,768
                                                           -------       ------

STOCKHOLDERS' EQUITY
    Preferred stock, par value $.10 per
       share - authorized, 1,000,000 shares;
       issued, none
    Common stock
       Class A (voting), par value $.10 per
          share - authorized, 6,000,000 shares;
          issued and outstanding  4,033,433 shares
          at November 27, 1999 and 4,035,346 shares
          at May 29, 1999 (excluding 1,913 shares
          held in treasury at November 27, 1999)               403          403
       Class B (nonvoting), par value $.10 per
          share - authorized, 10,000,000 shares;
          issued  and  outstanding 6,039,944 shares
          at November 27, 1999 and 6,058,277 shares
          at May 29, 1999 (excluding 65,774 and
          12,100 shares held in treasury at November
          27, 1999 and May 29, 1999, respectively)             604          606
    Additional paid-in capital                              21,794       21,917
    Retained earnings                                       57,502       53,887
    Accumulated other comprehensive income (loss)             (473)      (1,522)
                                                           -------       ------

          Total stockholders' equity                        79,830       75,291
                                                           -------       ------

                                                          $101,848      $96,059
                                                           =======       ======




The accompanying notes are an integral part of these statements.


                                      -4-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

                       CONSOLIDATED STATEMENTS OF EARNINGS
                                   (unaudited)
                      (in thousands, except per share data)


<TABLE>
<CAPTION>
                                            Thirteen weeks ended           Twenty-six weeks ended
                                        ----------------------------    ----------------------------
                                        November 27,    November 28,    November 27,    November 28,
                                            1999            1998            1999            1998
                                           ------          ------          ------          ------

<S>                                       <C>             <C>             <C>             <C>
Net sales                                 $27,973         $26,508         $55,170         $52,173

Cost of goods sold                         14,739          14,970          29,853          29,966
                                           ------          ------          ------          ------

      Gross profit                         13,234          11,538          25,317          22,207
                                           ------          ------          ------          ------

Operating expenses
  Selling and administrative                9,332           8,460          17,669          16,077
  Research and development                  1,171           1,229           2,372           2,231
                                           ------           -----          ------          ------

    Total operating expenses               10,503           9,689          20,041          18,308
                                           ------           -----          ------          ------

      Operating profit                      2,731           1,849           5,276           3,899

Other income (expense)
  Interest income                             146             138             291             257
  Interest expense                            (58)            (61)           (119)           (123)
  Equity in losses of affiliate                               (59)                           (138)
  Other, net                                  (19)            345              62             382
                                            -----           -----           -----           -----

      Earnings before income
        taxes                               2,800           2,212           5,510           4,277

Income tax provision                          983             684           1,895           1,279
                                            -----           -----           -----           -----

      NET EARNINGS                        $ 1,817         $ 1,528         $ 3,615         $ 2,998
                                            =====           =====           =====           =====

Earnings per common share
  Basic                                   $   .18         $   .15         $   .36         $   .30
                                            =====           =====           =====           =====

  Diluted                                 $   .18         $   .15         $   .35         $   .29
                                            =====           =====           =====           =====

Weighted average common shares
  Basic                                    10,074          10,076          10,074          10,060
                                           ======          ======          ======          ======

  Diluted                                  10,217          10,325          10,223          10,326
                                           ======          ======          ======          ======
</TABLE>




The accompanying notes are an integral part of these statements.


                                      -5-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

     CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME

                    Twenty-six weeks ended November 27, 1999
                                   (unaudited)
                        (in thousands, except share data)


<TABLE>
<CAPTION>
                                     Class A              Class B                                 Accumulated
                                   common stock         common stock      Additional                 other                  Compre-
                                ------------------   ------------------    paid-in     Retained   comprehensive             hensive
                                  Shares    Amount     Shares    Amount    capital     earnings   income (loss)    Total    income
                                ---------   ------   ---------   ------   ----------   --------   -------------   -------   ------

<S>                             <C>          <C>     <C>          <C>      <C>         <C>          <C>           <C>        <C>
Balance at May 29, 1999         4,035,346    $403    6,058,277    $606     $21,917     $53,887      $(1,522)      $75,291

Exercise of stock options                               20,066       2          77                                     79
Income tax benefits on
  stock options exercised                                                        8                                      8
Compensation related to
  stock option plans                                                             3                                      3
Issuance of stock                                       15,275       2          74                                     76
Purchase of treasury stock         (1,913)             (53,674)     (6)       (285)                                  (291)
Net earnings                                                                             3,615                      3,615    $3,615
Unrealized holding gain on debt
  and equity securities                                                                               1,252         1,252     1,252
Foreign currency translation
  adjustments                                                                                          (203)         (203)     (203)
                                ---------     ---    ---------     ---      ------      ------        -----        ------     -----

Comprehensive income                                                                                                         $4,664
                                                                                                                              =====

Balance at November 27, 1999    4,033,433    $403    6,039,944    $604     $21,794     $57,502      $  (473)      $79,830
                                =========     ===    =========     ===      ======      ======        =====        ======

</TABLE>




The accompanying notes are an integral part of this statement.


                                      -6-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)
                                 (in thousands)


                                                     Twenty-six weeks ended
                                                     ----------------------
                                                   November 27,    November 28,
                                                      1999            1998
                                                     ------          ------

Cash flows from operating activities:
  Net earnings                                       $ 3,615         $2,998
  Adjustments to reconcile net earnings
    to net cash provided by operating
    activities
      Depreciation and amortization                    1,431          1,442
      Provision for doubtful accounts                     76            121
      Equity in losses of affiliate                                     138
      Deferred income tax provision                       31             12
      Other non-cash items                                73             31
      Changes in operating assets and
        liabilities
          Accounts receivable                         (1,999)          (150)
          Inventories                                 (1,197)           (79)
          Other current assets                           594            (29)
          Other assets                                  (165)          (161)
          Accounts payable                             1,258           (118)
          Accrued liabilities                            298            582
          Accrued income taxes                          (164)           178
          Other noncurrent liabilities                    74             74
                                                      ------          -----

            Net cash provided by operating
              activities                               3,925          5,039
                                                      ------          -----

Cash flows from investing activities:
  Additions to property, plant and
    equipment, net                                      (985)          (941)
  Available-for-sale securities
    Purchases                                        (20,278)        (2,360)
    Proceeds from sale                                16,620          2,258
  Increase in certificates of deposit                                (1,075)
                                                      ------          -----

      Net cash used in investing activities           (4,643)        (2,118)
                                                      ------          -----

Cash flows from financing activities:
  Repayments of debt                                    (904)        (1,987)
  Proceeds from issuance of debt                          26
  Proceeds from exercise of stock options,
    including related income tax benefits                 87            253
  Purchase of treasury stock                            (291)
  Proceeds from issuance of stock in connection
    with the stock purchase plan                           6              2
                                                      ------          -----

      Net cash used in financing activities           (1,076)        (1,732)
                                                      ------          -----




                                      -7-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

                CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
                                   (unaudited)
                                 (in thousands)


                                                     Twenty-six weeks ended
                                                     ----------------------
                                                   November 27,   November 28,
                                                      1999           1998
                                                     ------         ------


Effect of exchange rate changes on
  cash and cash equivalents                          $  133         $ (694)
                                                      -----          -----

      (DECREASE) INCREASE IN CASH
        AND CASH EQUIVALENTS                         (1,661)           495

Cash and cash equivalents
  Beginning of period                                 8,073          4,654
                                                      -----          -----

  End of period                                      $6,412         $5,149
                                                      =====          =====

Supplemental disclosures of cash
  flow information:
    Cash paid during the period for:
      Interest                                       $   42         $   71
                                                      =====          =====

      Income taxes                                   $1,983         $1,332
                                                      =====          =====




The accompanying notes are an integral part of these statements.


                                      -8-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                     November 27, 1999 and November 28, 1998
                                   (unaudited)


NOTE A - CONSOLIDATED FINANCIAL STATEMENTS

     The  consolidated  balance sheet as of November 27, 1999, the  consolidated
     statement of stockholders'  equity and comprehensive  income for the period
     ended  November 27, 1999, and the  consolidated  statements of earnings and
     cash flows for the periods  ended  November 27, 1999 and November 28, 1998,
     have  been  prepared  by the  Company  without  audit.  In the  opinion  of
     management,   all  adjustments   (which  include  only  normally  recurring
     adjustments) necessary to present fairly the financial position, changes in
     stockholders'  equity and comprehensive  income,  results of operations and
     cash flows at November 27, 1999 (and for all periods  presented)  have been
     made.

     Certain  information  and  footnote   disclosures,   normally  included  in
     financial   statements  prepared  in  accordance  with  generally  accepted
     accounting principles, have been condensed or omitted. It is suggested that
     these  consolidated  financial  statements be read in conjunction  with the
     financial  statements and notes thereto  included in the fiscal 1999 Annual
     Report on Form 10-K filed by the Company on August 27, 1999. The results of
     operations  for the periods  ended  November 27, 1999 and November 28, 1998
     are not necessarily  indicative of the operating results for the respective
     full years.

     The consolidated  financial statements include the accounts of E-Z-EM, Inc.
     and  all  100%-owned   subsidiaries   (the   "Company").   All  significant
     intercompany balances and transactions have been eliminated.  The Company's
     approximate  23% interest in an affiliate in fiscal 1999 was  accounted for
     by the equity method. Pursuant to this method, such investment was recorded
     at cost and adjusted by the Company's share of  undistributed  earnings (or
     losses).  In the  fourth  quarter of the prior  fiscal  year,  the  Company
     recorded an impairment  charge, as it was determined that the fair value of
     such investment was zero, with no future cash flows  anticipated due to the
     affiliate's   inability  to  generate   income  from  operations  or  raise
     additional capital.


NOTE B - INVENTORIES

     Inventories consist of the following:

                                            November 27,        May 29,
                                               1999              1999
                                              ------            ------
                                                   (in thousands)

       Finished goods                         $13,631          $14,000
       Work in process                          2,116            1,926
       Raw materials                           12,424           11,048
                                               ------           ------

                                              $28,171          $26,974
                                               ======           ======


                                      -9-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                     November 27, 1999 and November 28, 1998
                                   (unaudited)


NOTE C - EARNINGS PER COMMON SHARE

     In accordance with Statement of Financial Accounting Standards ("SFAS") No.
     128,  "Earnings  Per Share," the Company has  presented  basic and dilutive
     earnings  per share.  Basic  earnings  per share are based on the  weighted
     average  number of  common  shares  outstanding  without  consideration  of
     potential  common  stock.  Diluted  earnings  per  share  are  based on the
     weighted average number of common and potential common shares  outstanding.
     The  calculation  takes into  account  the shares  that may be issued  upon
     exercise of stock  options,  reduced by the shares that may be  repurchased
     with the funds  received  from the  exercise,  based on the  average  price
     during the period.

     The following table sets forth the  reconciliation  of the weighted average
     number of common shares:

<TABLE>
                                    Thirteen weeks ended         Twenty-six weeks ended
                                 ---------------------------   ---------------------------
                                 November 27,   November 28,   November 27,   November 28,
                                     1999           1998           1999           1998
                                    ------         ------         ------         ------
                                                       (in thousands)

       <S>                          <C>            <C>            <C>            <C>
       Basic                        10,074         10,076         10,074         10,060
       Effect of dilutive
         securities (stock
         options)                      143            249            149            266
                                    ------         ------         ------         ------

       Diluted                      10,217         10,325         10,223         10,326
                                    ======         ======         ======         ======
</TABLE>


NOTE D - COMMON STOCK

     Under the 1983 and 1984 Stock Option Plans, options for 172,359 shares were
     granted at $5.63 per share,  options for 20,066  shares were  exercised  at
     prices  ranging  from $3.66 to $4.22 per share,  options for 13,944  shares
     were forfeited at prices ranging from $4.22 to $8.58 per share, and options
     for 5,970 shares  expired at $10.73 per share during the  twenty-six  weeks
     ended November 27, 1999.  Under the 1997  AngioDynamics  Stock Option Plan,
     options for 5.68 shares were granted at $40,000 per share,  options for .85
     shares were  forfeited at $40,000 per share,  and no options were exercised
     or expired during the twenty-six weeks ended November 27, 1999.

     Under the Employee  Stock  Purchase  Plan,  1,275 shares were  purchased at
     $4.46 per share during the twenty-six weeks ended November 27, 1999.

     In January 1999,  the Board of Directors  authorized  the repurchase of the
     Company's  Class B  Common  Stock  up to an  aggregate  purchase  price  of
     $2,000,000.  In October 1999, the Board modified the program to include the
     Company's  Class A Common Stock.  As of November 27, 1999,  the Company had
     repurchased 1,913 shares of Class A Common Stock and 65,774 shares of Class
     B Common Stock for approximately $359,000.




                                      -10-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                     November 27, 1999 and November 28, 1998
                                   (unaudited)


NOTE E - COMPREHENSIVE INCOME

     During  fiscal  1999,  the  Company   adopted  SFAS  No.  130,   "Reporting
     Comprehensive Income." SFAS No. 130 establishes new rules for the reporting
     and  display of  comprehensive  income  and its  components;  however,  the
     adoption  of SFAS No. 130 had no impact on the  Company's  net  earnings or
     stockholders'  equity.  SFAS No. 130 requires  unrealized  holding gains or
     losses on debt and  equity  securities  available-for-sale  and  cumulative
     translation  adjustments,  which prior to adoption were reported separately
     in stockholders'  equity, to be included in accumulated other comprehensive
     income (loss).

     The components of comprehensive income, net of related tax, are as follows:

                                                    Twenty-six weeks ended
                                                    ----------------------
                                                   November 27,    November 28,
                                                      1999            1998
                                                     ------          ------
                                                         (in thousands)

       Net earnings                                  $3,615          $2,998
       Unrealized holding gain (loss) on
         debt and equity securities                   1,252            (127)
       Foreign currency translation
         adjustments                                   (203)           (894)
                                                      -----           -----

           Comprehensive income                      $4,664          $1,977
                                                      =====           =====


    The  components of accumulated  other  comprehensive  income (loss),  net of
    related tax, are as follows:

                                                     November 27,      May 29,
                                                        1999            1999
                                                       ------          ------
                                                           (in thousands)

       Unrealized holding gain on debt
         and equity securities                        $ 2,445          $ 1,193
       Cumulative translation adjustments              (2,918)          (2,715)
                                                        -----            -----

           Accumulated other comprehensive income
             (loss)                                   $  (473)         $(1,522)
                                                        =====            =====


NOTE F - OPERATING SEGMENTS

     In fiscal  1999,  the  Company  adopted  SFAS No. 131,  "Disclosures  about
     Segments of an Enterprise and Related Information". The statement redefines
     how operating  segments are determined  and requires  disclosure of certain
     financial and descriptive information about a company's operating segments.
     The Company has adopted the new requirements retroactively.

     The  Company is  engaged  in the  manufacture  and  distribution  of a wide
     variety of  products  which are  classified  into two  operating  segments:
     Diagnostic  products  and  AngioDynamics   products.   Diagnostic  products
     encompass both contrast systems,  consisting of barium sulfate formulations
     and related


                                      -11-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                     November 27, 1999 and November 28, 1998
                                   (unaudited)


NOTE F - OPERATING SEGMENTS (continued)

     medical  devices  used in X-ray,  CT-scanning,  ultrasound  and MRI imaging
     examinations,  and non-contrast  systems,  including  diagnostic  radiology
     devices,  custom  contract  pharmaceuticals,   gastrointestinal   cleansing
     laxatives, X-ray protection equipment, and immunoassay tests. AngioDynamics
     products include angiography, therapeutic and coronary medical devices used
     in the interventional medical marketplace.

     The Company's chief operating decision maker utilizes operating segment net
     earnings  (loss)  information in assessing  performance  and making overall
     operating  decisions  and  resource  allocations.   Information  about  the
     Company's segments is as follows:

<TABLE>
<CAPTION>
                                           Thirteen weeks ended            Twenty-six weeks ended
                                        ---------------------------    -----------------------------
                                        November 27,   November 28,    November 27,     November 28,
                                            1999           1998            1999             1998
                                           ------         ------          ------           ------
                                                              (in thousands)

    <S>                                   <C>             <C>             <C>             <C>
    Net sales from external
    customers
      Diagnostic products
        Contrast systems                  $17,178         $15,729         $33,205         $29,877
        Non-contrast systems                6,269           5,851          13,098          11,693
                                           ------          ------          ------          ------

        Total Diagnostic products          23,447          21,580          46,303          41,570
      AngioDynamics products                4,526           4,928           8,867          10,603
                                           ------          ------          ------          ------

    Total net sales from external
      customers                           $27,973         $26,508         $55,170         $52,173
                                           ======          ======          ======          ======

    Intersegment net sales
      Diagnostic products                 $  (189)        $    15         $     2         $    26
      AngioDynamics products                  167             112             325             254
                                           ------          ------          ------          ------

    Total intersegment net sales          $   (22)        $   127         $   327         $   280
                                           ======          ======          ======          ======

    Net earnings (loss)
      Diagnostic products                 $ 2,327         $ 1,596         $ 4,637         $ 2,912
      AngioDynamics products                 (522)            (71)         (1,058)             89
      Eliminations                             12               3              36              (3)
                                           ------          ------          ------          ------

    Total net earnings                    $ 1,817         $ 1,528         $ 3,615         $ 2,998
                                           ======          ======          ======          ======

<CAPTION>
                                                                       November 27,        May 29,
                                                                           1999             1999
                                                                          ------           ------
                                                                               (in thousands)

     Assets
       Diagnostic products                                               $113,765        $107,027
       AngioDynamics products                                              17,579          17,922
       Eliminations                                                       (29,496)        (28,890)
                                                                          -------         -------

     Total assets                                                        $101,848        $ 96,059
                                                                          =======         =======
</TABLE>




                                      -12-
<PAGE>



                          E-Z-EM, Inc. and Subsidiaries

                      MANAGEMENT'S DISCUSSION AND ANALYSIS
                OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Quarters ended November 27, 1999 and November 28, 1998
------------------------------------------------------

     The Company's  quarters  ended November 27, 1999 and November 28, 1998 both
represent thirteen weeks.

Results of Operations
---------------------

     Segment Overview
     ----------------

     The Company  operates in two  industry  segments:  Diagnostic  products and
AngioDynamics  products. The Diagnostic products operating segment includes both
contrast systems and non-contrast systems. The AngioDynamics  products operating
segment includes  angiography,  therapeutic and coronary medical devices used in
the interventional medical marketplace.

<TABLE>
<CAPTION>
                                     Diagnostic   AngioDynamics   Eliminations     Total
                                     ----------   -------------   ------------     -----
                                                     (in thousands)

<S>                                    <C>            <C>            <C>          <C>
Quarter ended November 27, 1999
-------------------------------
 Unaffiliated customer sales           $23,447        $4,526            -         $27,973
 Intersegment sales                       (189)          167           $22            -
 Gross profit                           11,123         2,100            11         13,234
 Operating profit (loss)                 3,127          (408)           12          2,731

Quarter ended November 28, 1998
-------------------------------
 Unaffiliated customer sales           $21,580        $4,928            -         $26,508
 Intersegment sales                         15           112         ($127)           -
 Gross profit (loss)                     9,168         2,374            (4)        11,538
 Operating profit (loss)                 2,041          (195)            3          1,849
</TABLE>

     Diagnostic Products
     -------------------

     Diagnostic  segment  operating  results for the current quarter improved by
$1,086,000 due primarily to increased sales and improved gross profit, partially
offset by increased  operating expenses of $869,000.  Net sales increased 9%, or
$1,867,000,  due to increased demand for sales of both contrast systems and non-
contrast  systems.  Price  increases  accounted for  approximately 4 1/2% of net
sales in the current  quarter.  Gross profit  expressed  as a percentage  of net
sales  improved  to 48%  during  the  current  quarter,  versus  42%  during the
comparable  quarter of the prior year due  primarily  to sales price  increases,
increased  production  throughput and decreased provision for inventory reserves
of $335,000.

     AngioDynamics Products
     ----------------------

     AngioDynamics segment operating results for the current quarter declined by
$213,000 due to decreased  sales and gross  profit.  Net sales  decreased 8%, or
$402,000,  due primarily to lower than expected sales of  therapeutic  products,
resulting from the suspension of the sale of the clot-dissolving drug abbokinase
by Abbott Laboratories in the domestic  marketplace,  and reduced  international
sales,  resulting,  in large part,  from the  continued  decline in sales of the
AngioStent(TM).  Abbokinase  is the  primary  drug used in  connection  with the
Company's  therapeutic  products.  Gross profit expressed as a percentage of net
sales  decreased  to 45%  during  the  current  quarter  versus  47%  during the
comparable  quarter  of the prior year due  primarily  to  decreased  production
throughput at both the Queensbury, New York and Irish facilities.


                                      -13-
<PAGE>


     Consolidated Results of Operations
     ----------------------------------

     For the quarter ended November 27, 1999, the Company  reported net earnings
of $1,817,000,  or $.18 per common share on both a basic and diluted  basis,  as
compared to net earnings of $1,528,000, or $.15 per common share on both a basic
and  diluted  basis,  for the  comparable  period of last year.  Results for the
current  quarter were favorably  affected by increased  sales and improved gross
profit in the Diagnostic segment,  partially offset by decreased sales and gross
profit in the AngioDynamics  segment, as well as increased operating expenses in
the Diagnostic segment.

     Net  sales  for the  quarter  ended  November  27,  1999  increased  6%, or
$1,465,000,  as compared to the quarter ended November 28, 1998 due to increased
sales of contrast  systems of $1,449,000 and  non-contrast  systems of $418,000,
partially offset by decreased sales of AngioDynamics products of $402,000. Price
increases  accounted for  approximately  4% of net sales in the current quarter.
Net sales in  international  markets,  including  direct  exports from the U.S.,
increased 4%, or $355,000,  in the current quarter versus the comparable  period
of last year due to  increased  sales of contrast  systems of $483,000  and non-
contrast  systems  of  $81,000,  partially  offset  by a  decline  in  sales  of
AngioDynamics products of $209,000.

     Gross profit expressed as a percentage of net sales increased to 47% during
the current  quarter versus 44% during the comparable  quarter of the prior year
due to improved  gross profit in the  Diagnostic  segment,  partially  offset by
reduced gross profit in the AngioDynamics segment. The improved Diagnostic gross
profit  expressed as a percentage  of net sales is due  primarily to sales price
increases, increased production throughput and decreased provision for inventory
reserves of $335,000.  The decreased  AngioDynamics  gross profit expressed as a
percentage of net sales is due primarily to decreased  production  throughput at
both the Queensbury and Irish facilities.

     Selling and  administrative  ("S&A")  expenses were  $9,332,000  during the
quarter  ended  November  27, 1999 versus  $8,460,000  during the quarter  ended
November 28, 1998. This increase of $872,000, or 10%, in the current quarter was
due to increased  Diagnostic  S&A expenses,  which can be attributed to expenses
supporting the 9% sales increase during the current quarter.

     Research and development ("R&D")  expenditures  decreased 5% in the current
quarter to $1,171,000,  or 4% of net sales, from $1,229,000, or 5% of net sales,
in the comparable  quarter of the prior year.  This decline was due to decreased
spending  relating to  AngioDynamics  projects.  Of the R&D  expenditures in the
current  quarter,   approximately  48%  relate  to  contrast  systems,   30%  to
AngioDynamics  projects, 4% to immunological  projects, 4% to other projects and
14% to general  regulatory  costs.  R&D expenditures are expected to continue at
approximately current levels.

     Other  income,  net of other  expenses,  totaled  $69,000  of income in the
current quarter versus $363,000 of income in the comparable period of last year.
This decline was due to foreign currency  exchange gains of $297,000 recorded in
the comparable period of the prior year.

     The Company's  effective tax rate of 35% during the quarter ended  November
27, 1999  differed  from the Federal  statutory tax rate of 34% due primarily to
losses  incurred in a foreign  jurisdiction  subject to lower tax rates and non-
deductible  expenses,  mostly offset by earnings of the  Company's  Puerto Rican
subsidiary,  which are subject to favorable U.S. tax treatment.  For the quarter
ended November 28, 1998,  the Company's  effective tax rate of 31% differed from
the  Federal  statutory  tax rate of 34% due  primarily  to the  utilization  of
previously  unrecorded tax credit carryforwards and earnings of the Puerto Rican
subsidiary, which are subject to favorable U.S. tax treatment,  partially offset
by non-deductible expenses.


                                      -14-
<PAGE>


Twenty-six weeks ended November 27, 1999 and November 28, 1998
--------------------------------------------------------------

Results of Operations
---------------------

     Segment Overview
     ----------------

<TABLE>
<CAPTION>
                                            Diagnostic   AngioDynamics   Eliminations    Total
                                            ----------   -------------   ------------    -----
                                                               (in thousands)

<S>                                           <C>           <C>             <C>         <C>
Twenty-six weeks ended November 27, 1999
----------------------------------------

 Unaffiliated customer sales                  $46,303       $ 8,867            -        $55,170
 Intersegment sales                                 2           325         ($327)          -
 Gross profit                                  21,168         4,115            34        25,317
 Operating profit (loss)                        6,056          (816)           36         5,276

Twenty-six weeks ended November 28, 1998
----------------------------------------

 Unaffiliated customer sales                  $41,570       $10,603            -        $52,173
 Intersegment sales                                26           254         ($280)          -
 Gross profit (loss)                           17,010         5,215           (18)       22,207
 Operating profit (loss)                        3,638           264            (3)        3,899
</TABLE>

     Diagnostic Products
     -------------------

     Diagnostic  segment  operating  results for the current period  improved by
$2,418,000 due primarily to increased sales and improved gross profit, partially
offset by increased  operating expenses of $1,740,000.  Net sales increased 11%,
or $4,733,000,  due to increased  demand for sales of both contrast  systems and
non-contrast  systems.  Price increases  accounted for  approximately  3% of net
sales in the current period. Gross profit expressed as a percentage of net sales
improved  to 46% during the  current  period,  versus 41% during the  comparable
period of the prior  year due  primarily  to sales  price  increases,  increased
production   throughput  and  decreased  provision  for  inventory  reserves  of
$388,000.

     AngioDynamics Products
     ----------------------

     AngioDynamics  segment operating results for the current period declined by
$1,080,000 due to decreased sales and gross profit.  Net sales decreased 16%, or
$1,736,000,  due primarily to lower than expected sales of therapeutic products,
resulting from the suspension of the sale of the clot-dissolving drug abbokinase
by Abbott Laboratories in the domestic  marketplace,  and reduced  international
sales,  resulting,  in large part,  from the  continued  decline in sales of the
AngioStent(TM). Gross profit expressed as a percentage of net sales decreased to
45% during the current  period  versus 48% during the  comparable  period of the
prior  year  due  primarily  to  decreased  production  throughput  at both  the
Queensbury and Irish facilities.

     Consolidated Results of Operations
     ----------------------------------

     For the twenty-six  weeks ended November 27, 1999, the Company reported net
earnings of $3,615,000, or $.36 and $.35 per common share on a basic and diluted
basis, respectively, as compared to net earnings of $2,998,000, or $.30 and $.29
per common share on a basic and diluted basis, respectively,  for the comparable
period of last year.  Results for the current period were favorably  affected by
increased sales and improved gross profit in the Diagnostic  segment,  partially
offset by decreased sales and gross profit in the AngioDynamics segment, as well
as increased operating expenses in the Diagnostic segment.

     Net sales for the twenty-six weeks ended November 27, 1999 increased 6%, or
$2,997,000,  as  compared  to the  twenty-six  weeks ended  November  28,  1998.
Increased sales of contrast  systems of $3,328,000 and  non-contrast  systems of
$1,405,000,  including  $740,000  relating to custom  contract,  were  partially
offset


                                      -15-
<PAGE>


by decreased  sales of  AngioDynamics  products of $1,736,000.  Price  increases
accounted for approximately 2 1/2% of net sales in the current period. Net sales
in international markets,  including direct exports from the U.S., increased 9%,
or $1,622,000,  in the current period versus the comparable  period of last year
due to  increased  sales of  contrast  systems of  $1,572,000  and  non-contrast
systems of $951,000, including $740,000 relating to custom contracts,  partially
offset by a decline in sales of AngioDynamics products of $901,000.

     Gross profit expressed as a percentage of net sales increased to 46% during
the current period versus 43% during the  comparable  period of last year due to
improved gross profit in the  Diagnostic  segment,  partially  offset by reduced
gross profit in the AngioDynamics  segment. The improved Diagnostic gross profit
expressed  as a  percentage  of  net  sales  is due  primarily  to  sales  price
increases, increased production throughput and decreased provision for inventory
reserves of $388,000.  The decreased  AngioDynamics  gross profit expressed as a
percentage of net sales is due primarily to decreased  production  throughput at
both the Queensbury and Irish facilities.

     S&A expenses were  $17,669,000  during the twenty-six  weeks ended November
27, 1999 versus $16,077,000 during the twenty-six weeks ended November 28, 1998.
This increase of $1,592,000,  or 10%, in the current period was due to increased
Diagnostic S&A expenses,  which can be attributed to expenses supporting the 11%
sales increase during the current period.

     R&D expenditures increased 6% in the current period to $2,372,000, or 4% of
net sales,  from  $2,231,000,  or 4% of net sales, in the comparable  prior year
period. This increase was due primarily to increased contrast system spending of
$118,000.  Of the R&D  expenditures  in the current  period,  approximately  47%
relate to contrast systems, 33% to AngioDynamics  projects,  3% to immunological
projects, 4% to other projects and 13% to general regulatory costs.

     Other  income,  net of other  expenses,  totaled  $234,000 of income in the
current period versus $378,000 of income in the comparable  period of last year.
This decline was due primarily to foreign  currency  exchange  gains of $281,000
recorded in the  comparable  period of the prior year,  partially  offset by the
recording of the  Company's  approximate  23% share in the losses of ITI Medical
Technologies, Inc. of $138,000 in the comparable period of last year.

     The Company's effective tax rate during the twenty-six weeks ended November
27, 1999  approximated the Federal statutory tax rate of 34%. Losses incurred in
a foreign  jurisdiction  subject to lower tax rates and non-deductible  expenses
were offset by earnings of the  Company's  Puerto  Rican  subsidiary,  which are
subject to favorable U.S. tax treatment. For the twenty-six weeks ended November
28, 1998,  the  Company's  effective  tax rate of 30% differed  from the Federal
statutory  tax  rate of 34%  due  primarily  to the  utilization  of  previously
unrecorded tax credit carryforwards and earnings of the Puerto Rican subsidiary,
which are subject to favorable  U.S.  tax  treatment,  partially  offset by non-
deductible expenses.

Liquidity and Capital Resources
-------------------------------

     During the twenty-six weeks ended November 27, 1999,  capital  expenditures
and debt  repayments  were funded by cash provided by operations.  The Company's
policy has been to fund capital requirements without incurring significant debt.
At November 27, 1999, debt (notes payable,  current maturities of long-term debt
and  long-term  debt) was  $1,941,000 as compared to $2,503,000 at May 29, 1999.
The Company has available  $5,405,000 under two bank lines of credit of which no
amounts were outstanding at November 27, 1999.

     At November 27, 1999,  approximately 66% of the Company's assets consist of
inventories,  accounts  receivable,  short-term debt and equity securities,  and
cash and cash  equivalents.  The  current  ratio is 4.05 to 1, with net  working
capital


                                      -16-
<PAGE>


of $53,329,000 at November 27, 1999, as compared to the current ratio of 3.71 to
1, with net working capital of $48,430,000 at May 29, 1999.

     In January 1999,  the Board of Directors  authorized  the repurchase of the
Company's Class B Common Stock up to an aggregate  purchase price of $2,000,000.
In October 1999, the Board modified the program to include the Company's Class A
Common Stock. As of November 27, 1999, the Company had repurchased  1,913 shares
of  Class A  Common  Stock  and  65,774  shares  of  Class B  Common  Stock  for
approximately $359,000.

     Year 2000 Compliance
     --------------------

     Management  developed  and  completed  its  plan to  modify  the  Company's
information  technology to recognize  the Year 2000.  The Year 2000 issue is the
result of computer  programs  being written using two digits rather than four to
define the applicable year. The plan had three distinct areas of focus;  namely,
traditional   information  systems,   technology  used  in  support  areas,  and
preparedness of suppliers and customers.

     The  first  area of focus  was an  assessment  of  traditional  information
technology, namely internal software business applications, hardware and desktop
support. All of the Company's software systems, applications and desktop support
have been assessed, modified and tested to be Year 2000 compliant.

     The second area of focus was an assessment  of  technology  used in support
areas,  which includes the  electronics in  manufacturing  equipment,  telephone
systems,  security  systems  and  payroll  time  clocks.  At the  present  time,
substantially  all such  equipment  has either  been  tested to assure Year 2000
compliance or has been certified by vendors to be Year 2000 compliant.

     The third area of focus was communications  with suppliers and customers to
understand  their level of readiness  and assure a constant flow of materials to
support  business plans. The Company sought  compliance  statements from each of
its significant suppliers. Communication has shown a high level of awareness and
planning by these parties,  most of which have provided  positive  assurances to
maintain a constant flow of materials. At the present time, no material problems
or concerns are indicated by these responses.  However,  if a significant vendor
or  customer is  non-compliant,  the  Company  can give no  assurance  that such
occurrence will not have an adverse affect on the Company's results. The Company
believes  its action  plans will  minimize  these  risks and  prevent  any major
interruptions in the flow of materials and products.

     Formal  contingency plans were not formulated since the Company  identified
no  specific  areas  where there was a  substantial  risk of year 2000  problems
occurring.

     The plan was administered by internal staff and management.  Costs incurred
in the Company's readiness effort, which approximated $130,000, were expensed as
incurred,  except  for  those  costs  capitalized  as fixed  assets.  Management
believes  that the  Company  has met its  compliance  goals and,  to date,  this
project has not had a material  impact on the  Company's  operations,  though no
future assurance can be given in this regard.

     Forward-Looking Statements
     --------------------------

     This Form 10-Q  contains  certain  forward-looking  statements  within  the
meaning  of  Section  27A of  the  Securities  Act  of  1933,  as  amended  (the
"Securities  Act"),  and Section 21E of the Securities  Exchange Act of 1934, as
amended  (the  "Exchange  Act"),  which are  intended  to be covered by the safe
harbors  created  thereby.  Investors  are  cautioned  that all  forward-looking
statements  involve risks and uncertainty,  including  without  limitation,  the
ability of the  Company  to  develop  its  products,  as well as general  market
conditions, competition and


                                      -17-
<PAGE>



pricing.  Although the Company  believes  that the  assumptions  underlying  the
forward-looking   statements  contained  herein  are  reasonable,   any  of  the
assumptions could be inaccurate,  and therefore,  there can be no assurance that
the  forward-looking  statements  included  in this Form  10-Q will  prove to be
accurate.   In  light  of  the   significant   uncertainties   inherent  in  the
forward-looking  statements  included herein,  the inclusion of such information
should not be regarded as a  representation  by the Company or any other  person
that the objectives and plans of the Company will be achieved.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
        ----------------------------------------------------------

     The  Company  is exposed to market  risk from  changes in foreign  currency
exchange rates and, to a much lesser extent,  interest rates on investments  and
financing,  which could impact results of operations and financial position. The
Company does not  currently  engage in hedging or other  market risk  management
tools.  There  have  been no  material  changes  with  respect  to  market  risk
previously disclosed in the fiscal 1999 Annual Report on Form 10-K.

     Foreign Currency Exchange Rate Risk
     -----------------------------------

     The Company's  international  subsidiaries  are  denominated  in currencies
other  than the U.S.  dollar.  However,  since the  functional  currency  of the
Company's  international  subsidiaries is the local currency,  foreign  currency
translation  adjustments  are  accumulated as a component of  accumulated  other
comprehensive  income (loss) in  stockholders'  equity.  Assuming a hypothetical
change in the foreign  currency  versus the U.S. dollar exchange rates of 10% at
November  27, 1999,  the  Company's  assets and  liabilities  would  increase or
decrease by $2,422,000 and $748,000,  respectively,  and the Company's net sales
and net  earnings  would  increase  or  decrease  by  $2,368,000  and  $138,000,
respectively, on an annual basis.

     The Company also maintains  intercompany balances and loans receivable with
subsidiaries  with  different  local  currencies.  These  amounts are at risk of
foreign  exchange  losses if exchange rates  fluctuate.  Assuming a hypothetical
change in the foreign  currency  versus the U.S. dollar exchange rates of 10% at
November  27, 1999,  results of  operations  would be  favorably or  unfavorably
impacted by approximately $945,000 on an annual basis.

     Interest Rate Risk
     ------------------

     The Company is exposed to interest  rate change market risk with respect to
its  investments in tax-free  municipal  bonds in the amount of $8,800,000.  The
bonds bear interest at a floating rate established weekly. During the twenty-six
weeks ended November 27, 1999, the interest rate on the bonds approximated 3.6%.
Each 100 basis  point  (1%)  fluctuation  in  interest  rates will  increase  or
decrease  interest  income on the bonds by  approximately  $88,000  on an annual
basis.

     As  the  Company's  principal  amount  of  fixed  interest  rate  financing
approximates  $1,941,000 at November 27, 1999, a change in interest  rates would
not materially impact results of operations or financial  position.  At November
27, 1999, the Company did not maintain any variable interest rate financing.


                                      -18-
<PAGE>


                          E-Z-EM, Inc. and Subsidiaries

                           Part II: Other Information


Item 4. Submission of Matters to a Vote of Security Holders
        ---------------------------------------------------

     At the Annual Meeting of Shareholders  held October 19, 1999, the following
persons were elected as Directors of the Company:

        Class III Directors:  (until the 2002 Annual Meeting)
        -------------------

             Howard S. Stern
             David P. Meyers

     In this election, 3,337,004 and 3,335,004 votes were cast for Mr. Stern and
Mr.  Meyers,  respectively,  and 378,780 and 380,780  shares were  withheld from
voting for Mr. Stern and Mr. Meyers, respectively.

     The following Directors continue in office for the duration of their terms:

        Class I Directors:  (until the 2000 Annual Meeting)
        -----------------

             Michael A. Davis, M.D.
             James L. Katz, CPA, JD

        Class II Directors:  (until the 2001 Annual Meeting)
        ------------------

             Paul S. Echenberg
             Donald A. Meyer
             Robert M. Topol

     A proposed  amendment to the  Company's  1983 Stock Option Plan to increase
the number of authorized shares reserved for issuance pursuant to the 1983 Stock
Option Plan by 800,000 from  1,817,974  to  2,617,974  was approved by a vote of
3,021,825 in favor, 444,759 against, 4,720 shares abstaining, and 244,480 broker
non-votes.

     The action of the Board of Directors in  appointing  Grant  Thornton LLP as
the Company's  independent  auditors for fiscal year 2000 was approved by a vote
of 3,711,055 in favor, 576 against, and 4,153 shares abstaining.

Item 6. Exhibits and Reports on Form 8-K
        --------------------------------

(a)  Exhibits
     --------

     No.  Description                                            Page
     ---  -----------                                            ----

     27   Financial data schedule                                 21

(b)  Reports on Form 8-K
     -------------------

     No reports on Form 8-K were filed  during the quarter  ended  November  27,
     1999.


                                      -19-
<PAGE>


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                          E-Z-EM, Inc.
                                         ---------------------------------------
                                          (Registrant)




Date   January 10, 2000                   /s/ Howard S. Stern
     --------------------                ---------------------------------------
                                          Howard S. Stern, Chairman of the
                                          Board, President, Chief Executive
                                          Officer and Director




Date   January 10, 2000                   /s/ Dennis J. Curtin
     --------------------                ---------------------------------------
                                          Dennis J. Curtin, Senior Vice
                                          President - Chief Financial Officer


                                      -20-